- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05485779
SAD, MAD and Food Effect Evaluation of Safety, Tolerability, and PK of AQ280 in Healthy Subjects
A Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose, and Food Effect Evaluation Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of AQ280 in Healthy Subjects
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Leeds, United Kingdom, LS2 9LH
- Fortrea Clinical Research Unit Ltd.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Subjects must satisfy all of the following criteria at the screening visit (and/or at check-in, where noted):
- Males or females, of any race, between 18 and 65 years of age, inclusive.
- Body mass index between 18.0 and 32.0 kg/m2, inclusive.
- In good health, determined by no clinically significant findings from medical history, 12 lead ECG, vital sign measurements, and clinical laboratory evaluations at screening and check-in and from the physical examination at check-in, as assessed by the investigator (or designee).
- Females will not be pregnant or lactating, and females of childbearing potential and males will agree to use contraception.
- Able to comprehend and willing to sign an informed consent form (ICF) and to abide by the study restrictions.
Exclusion Criteria:
Subjects will be excluded from the study if they satisfy any of the following criteria at the screening visit (or at check-in, where noted):
Medical conditions
- Significant history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder, as determined by the investigator (or designee).
- History of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance, as determined by the investigator (or designee).
- History of any surgical (eg, stomach or intestinal surgery or resection) or medical condition that would potentially alter absorption, distribution, metabolism, and/or excretion of orally administered drugs. Uncomplicated appendectomy and hernia repair will be allowed. Cholecystectomy will not be allowed.
- History of any significant infectious disease, as assessed by the investigator, within 2 weeks prior to the first dose of IMP.
- Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) values >1.2 × upper limit of normal (ULN).
- Congenital nonhemolytic hyperbilirubinemia (including suspicion of Gilbert's syndrome).
- Hemoglobin value, neutrophil count, and/or lymphocyte count <lower limit of normal.
- Clinically significant abnormal ECG at screening or check-in.
- Positive hepatitis panel and/or positive human immunodeficiency virus test. Subjects whose results are compatible with prior immunization may be included at the discretion of the investigator
Current active tuberculosis based on Quantiferon™ tuberculosis Gold test.
Prior/concomitant therapy
- Administration of a coronavirus disease 2019 vaccine in the past 30 days prior to the first dose of investigational medicinal product (IMP).
- Use or intend to use any medications/products known to alter drug absorption, metabolism, or elimination processes, including St. John's wort, within 30 days prior to the first dose of IMP, unless deemed acceptable by the investigator (or designee).
- Use or intend to use any prescription medications/products other than hormone replacement therapy, oral, implantable, transdermal, injectable, or intrauterine contraceptives within 14 days prior to the first dose of IMP, unless deemed acceptable by the investigator (or designee).
- Use or intend to use slow release medications/products considered to still be active within 14 days prior to check in, unless deemed acceptable by the investigator (or designee).
Use or intend to use any nonprescription medications/products including vitamins, minerals, and phytotherapeutic/herbal/plant derived preparations within 7 days prior to check in, unless deemed acceptable by the investigator (or designee).
Prior/concurrent clinical study experience
- Participation in a clinical study involving administration of an investigational drug (new chemical entity) in the past 90 days prior to dosing.
Have previously completed or withdrawn from this study.
Diet and lifestyle
- Alcohol consumption of >21 units per week for males and >14 units for females. One unit of alcohol equals ½ pint (285 mL) of beer or lager, 1 glass (125 mL) of wine, or 1/6 gill (25 mL) of spirits.
- Positive alcohol breath test result or positive urine drug screen (confirmed by repeat) at screening or check-in.
- History of alcoholism or drug/chemical abuse within 2 years prior to check-in.
- Smoking >5 cigarettes per day, on average, or use the equivalent tobacco- or nicotine containing products per day.
Ingestion of poppy seed , Seville orange , star fruit-, or grapefruit containing foods or beverages within 7 days prior to check-in.
Other exclusions
- Receipt of blood products within 2 months prior to check-in.
- Donation of blood from 3 months prior to screening, plasma from 2 weeks prior to screening, or platelets from 6 weeks prior to screening.
- Poor peripheral venous access.
- Subjects who, in the opinion of the investigator (or designee), should not participate in this study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Part A (SAD): Group A1
Single dose of AQ280, 3 mg or placebo
|
Dose form: capsule, hard Strength: 3 to 100 mg Method of administration: oral Active substance: none Dose form: capsule, hard Strength/dose: not applicable Method of administration: oral |
Experimental: Part A (SAD): Group A2
Single dose of AQ280, dose to be determined (TBD) or placebo
|
Dose form: capsule, hard Strength: 3 to 100 mg Method of administration: oral Active substance: none Dose form: capsule, hard Strength/dose: not applicable Method of administration: oral |
Experimental: Part A (SAD): Group A3
Single dose of AQ280, dose TBD or placebo
|
Dose form: capsule, hard Strength: 3 to 100 mg Method of administration: oral Active substance: none Dose form: capsule, hard Strength/dose: not applicable Method of administration: oral |
Experimental: Part A (SAD): Group A4
Single dose of AQ280, dose TBD or placebo
|
Dose form: capsule, hard Strength: 3 to 100 mg Method of administration: oral Active substance: none Dose form: capsule, hard Strength/dose: not applicable Method of administration: oral |
Experimental: Part A (SAD): Group A5
Single dose of AQ280, dose TBD or placebo
|
Dose form: capsule, hard Strength: 3 to 100 mg Method of administration: oral Active substance: none Dose form: capsule, hard Strength/dose: not applicable Method of administration: oral |
Experimental: Part B (MAD): Group B1
AQ280 dose TBD or placebo, once daily (QD) for seven days
|
Dose form: capsule, hard Strength: 3 to 100 mg Method of administration: oral Active substance: none Dose form: capsule, hard Strength/dose: not applicable Method of administration: oral |
Experimental: Part B (MAD): Group B2
AQ280 dose TBD or placebo, once daily (QD) for seven days
|
Dose form: capsule, hard Strength: 3 to 100 mg Method of administration: oral Active substance: none Dose form: capsule, hard Strength/dose: not applicable Method of administration: oral |
Experimental: Part B (MAD): Group B3
AQ280 dose TBD or placebo, once daily (QD) for seven days
|
Dose form: capsule, hard Strength: 3 to 100 mg Method of administration: oral Active substance: none Dose form: capsule, hard Strength/dose: not applicable Method of administration: oral |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Part A (SAD): Number of treatment emergent adverse events (TEAEs) per subject
Time Frame: Part A (SAD): Screening up to Day 8(±2)
|
Part A (SAD): Screening up to Day 8(±2)
|
|
Part A (SAD): Number of subjects with clinically significant abnormalities in vital signs
Time Frame: Part A (SAD): Screening up to Day 3
|
Vital signs: systolic and diastolic blood pressure, pulse rate, and oral body temperature
|
Part A (SAD): Screening up to Day 3
|
Part A (SAD): Number of subjects with abnormal ECG
Time Frame: Part A (SAD): Screening up to Day 3
|
QTcF interval of >450 msec for males and >470 msec for females, or change from baseline of >30 msec
|
Part A (SAD): Screening up to Day 3
|
Part A (SAD): Number of subjects with clinically significant changes in laboratory evaluations
Time Frame: Part A (SAD): Screening up to Day 3
|
Part A (SAD): Screening up to Day 3
|
|
Part A (Food Effect): Number of treatment emergent adverse events (TEAEs) per subject
Time Frame: Part A (Food Effect): Screening up to Day 18(±2)
|
Part A (Food Effect): Screening up to Day 18(±2)
|
|
Part A (Food Effect): Number of subjects with clinically significant abnormalities in vital signs
Time Frame: Part A (Food Effect): Screening up to Day 13
|
Vital signs: systolic and diastolic blood pressure, pulse rate, and oral body temperature
|
Part A (Food Effect): Screening up to Day 13
|
Part A (Food Effect): Number of subjects with abnormal ECG
Time Frame: Part A (Food Effect): Screening up to Day 13
|
QTcF interval of >450 msec for males and >470 msec for females, or change from baseline of >30 msec
|
Part A (Food Effect): Screening up to Day 13
|
Part A (Food Effect): Number of subjects with clinically significant changes in laboratory evaluations
Time Frame: Part A (Food Effect): Screening up to Day 13
|
Part A (Food Effect): Screening up to Day 13
|
|
Part B (MAD): Number of treatment emergent adverse events (TEAEs) per subject
Time Frame: Part B (MAD): Screening up to Day 14(±3)
|
Part B (MAD): Screening up to Day 14(±3)
|
|
Part B (MAD): Number of subjects with clinically significant abnormalities in vital signs
Time Frame: Part B (MAD): Screening up to Day 14(±3)
|
Vital signs: systolic and diastolic blood pressure, pulse rate, and oral body temperature
|
Part B (MAD): Screening up to Day 14(±3)
|
Part B (MAD): Number of subjects with abnormal ECG
Time Frame: Part B (MAD): Screening up to Day 14(±3)
|
QTcF interval of >450 msec for males and >470 msec for females, or change from baseline of >30 msec
|
Part B (MAD): Screening up to Day 14(±3)
|
Part B (MAD): Number of subjects with clinically significant changes in laboratory evaluations
Time Frame: Part B (MAD): Screening up to Day 14(±3)
|
Part B (MAD): Screening up to Day 14(±3)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Part A (SAD) - Primary PK parameters derived from plasma concentration-time profile of AQ280: area under the concentration time curve from time 0 extrapolated to infinity
Time Frame: Days 1, 2 and 3
|
Area under the concentration time curve over a dosing interval (AUCτ) may be included as a primary PK parameter if AUC 0-infinity cannot be calculated
|
Days 1, 2 and 3
|
Part A (SAD) - Primary PK parameter derived from plasma concentration-time profile of AQ280: maximum observed concentration (Cmax)
Time Frame: Days 1, 2 and 3
|
Days 1, 2 and 3
|
|
Part A (SAD) - Primary PK parameter derived from plasma concentration-time profile of the AQ280 main metabolite, AQ282: area under the concentration time curve from time 0 extrapolated to infinity
Time Frame: Days 1, 2 and 3
|
Area under the concentration time curve over a dosing interval (AUCτ) may be included as a primary PK parameter if AUC 0-infinity cannot be calculated
|
Days 1, 2 and 3
|
Part A (SAD) - Primary PK parameter derived from plasma concentration-time profile of the AQ280 main metabolite, AQ282: maximum observed concentration (Cmax)
Time Frame: Days 1, 2 and 3
|
Days 1, 2 and 3
|
|
Part A (SAD) - Difference in Primary PK parameters derived from plasma concentration-time profile of AQ280: area under the concentration time curve from time 0 extrapolated to infinity in fasted state and in fed state
Time Frame: Days 1, 2 and 3
|
Area under the concentration time curve over a dosing interval (AUCτ) may be included as a primary PK parameter if AUC 0-infinity cannot be calculated
|
Days 1, 2 and 3
|
Part A (SAD) - Difference in Primary PK parameters derived from plasma concentration-time profile of AQ280: maximum observed concentration (Cmax) in fasted state and in fed state
Time Frame: Days 1, 2 and 3
|
Area under the concentration time curve over a dosing interval (AUCτ) may be included as a primary PK parameter if AUC 0-infinity cannot be calculated
|
Days 1, 2 and 3
|
Part B (MAD) - Primary PK parameters derived from plasma concentration-time profile of AQ280: accumulation ratio (AR)
Time Frame: Day 1 and Day 7
|
Day 1 and Day 7
|
|
Part B (MAD) - Primary PK parameters derived from plasma concentration-time profile of AQ280: area under the concentration time curve over a dosing interval (AUCτ)
Time Frame: Day 1 and Day 7
|
Day 1 and Day 7
|
|
Part B (MAD) - Primary PK parameters derived from plasma concentration-time profile of AQ280: maximum observed concentration (Cmax)
Time Frame: Day 1 and Day 7
|
Day 1 and Day 7
|
|
Part B (MAD) - Primary PK parameter derived from plasma concentration-time profile of the AQ280 main metabolite, AQ282: area under the concentration time curve over a dosing interval (AUCτ)
Time Frame: Day 1 and Day 7
|
Day 1 and Day 7
|
|
Part B (MAD) - Primary PK parameter derived from plasma concentration-time profile of the AQ280 main metabolite, AQ282: maximum observed concentration (Cmax)
Time Frame: Day 1 and Day 7
|
Day 1 and Day 7
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Jan Törnell, MD, PhD, AQILION AB
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ARIA-1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Eosinophilic Esophagitis (EoE)
-
ShireCompletedEosinophilic Esophagitis (EoE)United States
-
Children's Hospital of PhiladelphiaRecruitingEosinophilic Esophagitis (EoE)United States
-
Medical University of GrazRecruiting
-
Regeneron PharmaceuticalsSanofiActive, not recruitingEosinophilic Esophagitis (EoE)United States, Canada
-
ShireTakeda Development Center Americas, Inc.TerminatedEosinophilic Esophagitis (EoE)United States
-
ShireCompletedEosinophilic Esophagitis (EoE)United States
-
ShireCompleted
-
ShireCompletedEosinophilic Esophagitis (EoE)United States
-
University of IowaTerminated
-
Children's Hospital Medical Center, CincinnatiNational Institute of Allergy and Infectious Diseases (NIAID); National Institute... and other collaboratorsCompletedEosinophilic Esophagitis (EoE) | Eosinophilic Gastrointestinal Disorders (EGIDs)United States